These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1059 related articles for article (PubMed ID: 25877329)

  • 1. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NF1 gene in tumor syndromes and melanoma.
    Kiuru M; Busam KJ
    Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis 1: closing the GAP between mice and men.
    Dasgupta B; Gutmann DH
    Curr Opin Genet Dev; 2003 Feb; 13(1):20-7. PubMed ID: 12573431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer.
    Rad E; Tee AR
    Semin Cell Dev Biol; 2016 Apr; 52():39-46. PubMed ID: 26860753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular genetics of neurofibromatosis type 1].
    Suzuki H; Takahashi K; Shibahara S
    Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
    Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
    Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
    Feldkamp MM; Angelov L; Guha A
    Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NF1 somatic mutational landscape in sporadic human cancers.
    Philpott C; Tovell H; Frayling IM; Cooper DN; Upadhyaya M
    Hum Genomics; 2017 Jun; 11(1):13. PubMed ID: 28637487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations in the neurofibromatosis 1 gene in human tumors.
    Li Y; Bollag G; Clark R; Stevens J; Conroy L; Fults D; Ward K; Friedman E; Samowitz W; Robertson M
    Cell; 1992 Apr; 69(2):275-81. PubMed ID: 1568247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel diagnostic method to detect truncated neurofibromin in neurofibromatosis 1.
    Esposito T; Piluso G; Saracino D; Uccello R; Schettino C; Dato C; Capaldo G; Giugliano T; Varriale B; Paolisso G; Di Iorio G; Melone MA
    J Neurochem; 2015 Dec; 135(6):1123-8. PubMed ID: 26478990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetic and molecular pathogenesis of NF1 and NF2.
    Yohay KH
    Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis type 1 (NF1) gene: Beyond café au lait spots and dermal neurofibromas.
    Peltonen S; Kallionpää RA; Peltonen J
    Exp Dermatol; 2017 Jul; 26(7):645-648. PubMed ID: 27622733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?
    Fareez F; Wang BH; Brain I; Lu JQ
    Pathology; 2023 Apr; 55(3):302-314. PubMed ID: 36774237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel and Recurring Disease-Causing NF1 Variants in Two Chinese Families with Neurofibromatosis Type 1.
    Xiao H; Yuan L; Xu H; Yang Z; Huang F; Song Z; Yang Y; Zeng C; Deng H
    J Mol Neurosci; 2018 Aug; 65(4):557-563. PubMed ID: 30046999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
    Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
    Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofibromin and suppression of tumorigenesis: beyond the GAP.
    Mo J; Moye SL; McKay RM; Le LQ
    Oncogene; 2022 Feb; 41(9):1235-1251. PubMed ID: 35066574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
    Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
    Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.